Critical period for the development of spontaneous hypertension in rats.
D000818:Animals; D001927:Brain Diseases / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006145:Guanethidine / Q000627:therapeutic use*; D006571:Heterocyclic Compounds / Q000627:therapeutic use; D006834:Hydrazines / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007674:Kidney Diseases / Q000209:etiology; D008297:Male; D009400:Nephrosclerosis / Q000209:etiology; D010998:Pleurisy / Q000209:etiology; D010488:Polyarteritis Nodosa / Q000209:etiology; D001261:Pulmonary Atelectasis / Q000209:etiology; D011724:Pyridazines / Q000627:therapeutic use*; D051381:Rats; D012737:Sex Factors; D013997:Time Factors
D006571:Heterocyclic Compounds; D006834:Hydrazines; D011724:Pyridazines; D006145:Guanethidine